Linagliptin and Mesenchymal Stem Cells: A Pilot Study

• Status: Completed
• Trial end date: 2018-03-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nevada, Reno
• Collaborator: Augusta University
• Treatments: Linagliptin

Criteria

Inclusion Criteria:

• Meets DSM (Diagnostic and Statistical Manual) criteria for schizophrenia.

• Considered clinically stable, and on the same dose of antipsychotic for two weeks.

• A score no greater than 3 on the PANSS (Positive and Negative Syndrome Scale) Conceptual Disorganization item.

• Not taking any medications for diabetes, or any anti-inflammatories other than occasional aspirin or acetaminophen. Not taking Clozapine.

• Age 18-45 years.

• Can be available for regular morning appointments from 8:00 am to 10:00 am, preferably on Tuesdays, Wednesdays and Thursdays.

Exclusion Criteria:

• Does not meet DSM criteria for substance abuse or dependence.

• No serious current general medical condition, such as cancer, history of stroke or myocardial infarction, tuberculosis, HIV/AIDS, hemophilia, etc.